However, unlike previous studies about TLR7/8 agonist (50–54), our findings suggest that the systemic administration of R848 (1 mg/kg) did not evidently alter the composition of macrophages nor did it effectively promote type I macrophage polarization in murine liver cancer, and the percentage of DC cells in liver cancer and pancreatic cancer (27) was slightly decreased after R848 administration, which is inconsistent with the stronger antitumor immunity induced by R848—so further research is necessary. This evidence concerns the gene TLR7 and familial pancreatic carcinoma.